Neurogene
NGNE
88 hedge funds and large institutions have $265M invested in Neurogene in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 10 closing their positions.
584% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $284K
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
15% more capital invested
Capital invested by funds: $230M → $265M (+$35M)
7% more funds holding
Funds holding: 82 → 88 (+6)
0.7% less ownership
Funds ownership: 107.9% → 107.2% (-0.7%)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14M |
| 2 |
Jennison Associates
New York
|
+$4.55M |
| 3 |
Jane Street
New York
|
+$1.25M |
| 4 |
Goldman Sachs
New York
|
+$1.11M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$793K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.09M |
| 2 |
CC
Commodore Capital
New York
|
-$6.4M |
| 3 |
Morgan Stanley
New York
|
-$2.39M |
| 4 |
Millennium Management
New York
|
-$1.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.1M |
NGNE Hedge Fund Activity: Q3 2025 in Review
88 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2025, worth a combined $265M — up 15% from $230M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NGNE positions and 10 closed out — a net gain of 6 holders — while 23 added to existing stakes and 26 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $14M. The largest seller was Fidelity Investments, cutting an estimated $7.09M.
- 88 institutional investors held Neurogene (NGNE) as of Q3 2025, up from 82 in Q2 2025.
- Funds reported $265M of Neurogene stock for Q3 2025, up 15% quarter-over-quarter.
- 16 funds opened new Neurogene positions in Q3 2025 and 10 closed out, a net change of +6 holders.
- The largest Neurogene buyer in Q3 2025 was Balyasny Asset Management, an estimated $14M added.
- The largest Neurogene seller in Q3 2025 was Fidelity Investments, an estimated $7.09M sold.
Based on aggregated 13F filings for Q3 2025.